Background. Many patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumonia. Patients with minimal and stable ventilator settings may be suitable candidates for early antibiotic discontinuation. We compared outcomes among patients with suspected VAP but minimal and stable ventilator settings treated with 1-3 days vs >3 days of antibiotics.
Antibiotics administered for suspected respiratory infections account for 50%-70% of antibiotic prescribing in intensive care units (ICUs) [1] [2] [3] [4] . A substantial fraction of these antibiotic courses may be unnecessary. The predilection to overprescribe antibiotics for patients with possible ventilator-associated pneumonia (VAP) is not due to poor clinical skills per se, but rather the tension between practice guidelines that encourage early and aggressive prescribing arrayed against the difficulty of accurately diagnosing VAP. The clinical signs used to diagnose VAP, including fever, leukocytosis, increased secretions, and radiographic infiltrates, are common and nonspecific in ventilated patients. Case series comparing clinical diagnoses of VAP with autopsy or expert adjudication suggest that 40%-70% of patients diagnosed and treated for VAP do not have VAP [5] [6] [7] .
The challenge is to find simple, pragmatic strategies to help clinicians identify suitable candidates for early discontinuation of antibiotics. It is unrealistic to expect clinicians to withhold antibiotics when they first suspect VAP given the difficulty making a certain diagnosis and ample data associating delayed treatment with increased mortality [8] [9] [10] [11] [12] [13] [14] [15] [16] . Focusing on early discontinuation instead, once clinicians have had a chance to observe patients' clinical trajectories, may be more promising.
One potential strategy may be to evaluate patients' serial ventilator settings. Clinically significant pneumonias usually impair gas exchange and often require higher levels of ventilator support [17] [18] [19] [20] [21] . Conversely, patients with suspected VAP but minimal and stable ventilator settings may be candidates for stopping antibiotics early. These patients may not have pneumonia at all or they may have comparatively mild pneumonias that can be adequately treated with very short courses of antibiotics.
Given the potential value of serial ventilator setting surveillance to inform antibiotic stewardship efforts, we compared outcomes among patients started on empiric antibiotics for suspected VAP but minimal and stable ventilator settings who were treated with antibiotics for ≤3 days vs >3 days.
METHODS
We retrospectively identified all patients age ≥18 initiated on mechanical ventilation in Brigham and Women's Hospital between 1 January 2006 and 31 December 2014. Patients were identified using a prospectively populated database of patients on mechanical ventilation maintained by the hospital's respiratory therapy department. We then identified all patients started on antibiotics for possible VAP who had minimal and stable ventilator settings for at least 3 days. We defined minimal and stable ventilator settings as daily minimum positive end-expiratory pressure (PEEP) of ≤5 cm H 2 O and daily minimum fraction of inspired oxygen (FiO 2 ) of ≤40% on the day antibiotics were started and the following 2 calendar days. We obtained data on patients' microbiology, drug exposures, and clinical characteristics by merging the database of ventilated patients with the hospital's microbiology database, electronic medical administration record, and clinical data repository. The Partners' Institutional Research Board approved the study for waiver of informed consent.
For our primary analysis, we defined patients with suspected VAP as those in whom clinicians acquired an endotracheal aspirate or bronchoalveolar lavage culture on or after the third day of mechanical ventilation and initiated 1 or more new antibiotics within 2 calendar days of the culture order date (excluding the first 2 days of mechanical ventilation). We defined a new antibiotic as one that had not been administered in the preceding 2 calendar days.
We then compared outcomes among patients prescribed 1-3 days of antibiotics vs those prescribed >3 days of antibiotics. In determining the duration of antibiotics, we counted all consecutive antibiotic days wherein 1 or more of the antibiotics started at the time of the pulmonary culture were continued or a new antibiotic was substituted and continued. We included single days between 2 doses of levofloxacin and vancomycin, as well as the subsequent day, to account for renal dosing. We also reviewed all patients in the short-course group who received vancomycin on antibiotic day 3 and who had renal dysfunction (defined as creatinine ≥2.0 mg/dL). We manually extended their vancomycin course in accordance with their dosing history and daily vancomycin levels. We calculated duration of mechanical ventilation as the time from antibiotic start to extubation, and duration of hospitalization as the time from antibiotic start to hospital discharge. We excluded patients who died within 2 days of stopping antibiotics from the short-course arm insofar as we wished to restrict the analysis to patients in whom clinicians elected to stop antibiotics early rather than those in whom early antibiotic discontinuation was forced by early death.
We compared outcomes using Fine-Gray subdistribution hazard models to calculate the competing events of time to extubation alive vs ventilator death and time to hospital discharge alive vs hospital death [22] . We adjusted all analyses for age, race, sex, ICU type, predicted probability of hospital death on the first day of mechanical ventilation [23] , time from intubation until pneumonia, maximum temperature on the first day of antibiotics, maximum white blood cell count on the first day of antibiotics, use of vasopressors on the first day of antibiotics, presence of ≥25 neutrophils per low-power field on pulmonary specimen Gram stain, and positive cultures for Staphylococcus aureus, Enterobacter species, Klebsiella species, Serratia species, or non-fermenting gram-negative rods. We further adjusted for patients' comorbidities including chronic lung disease, renal failure, cancer, diabetes, peripheral vascular disease, congestive heart failure, coronary artery disease, liver disease, and alcohol abuse. Finally we adjusted for calendar year of diagnosis to account for possible temporal trends in management strategies and outcomes.
We performed 3 sensitivity analyses using propensity scores to match patients prescribed 1-3 days of antibiotics to patients prescribed >3 days of antibiotics. The first sensitivity analysis included all patients prescribed 1-3 days of antibiotics and their corresponding matches. The second sensitivity analysis was intended to identify a subset of patients with additional evidence that the clinical team specifically suspected VAP. To do so, we restricted the primary study population to patients assigned a pneumonia diagnosis code (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 481-486 or 997.31) for the first time in their hospitalization on or after ventilator day 3 and within 2 days of their respiratory culture and antibiotic start dates. The third sensitivity analysis was designed to identify a subset of patients with a greater likelihood of having a true pneumonia. To do so, we restricted the study population to patients with ≥25 neutrophils per lowpower field on endotracheal aspirate or bronchoalveolar lavage Gram stain and a positive culture for a potentially pathogenic organism (ie, organisms other than oral flora, Candida species, Enterococcus species, and coagulase-negative staphylococci). We calculated propensity scores by fitting logistic regression models using all the same covariates used in the primary analysis. We identified a match for each patient treated with 1-3 days of antibiotics by identifying the patient treated with >3 days of antibiotics with the closest estimated logit propensity score [24] . To assure close matches, we imposed a caliper of 0.2 times the standard deviation of the logit propensity score for each patient [25] .
RESULTS
There were 30 336 episodes of mechanical ventilation between 2006 and 2014. Of these, 2549 (8.4%) met the primary study definition for clinically suspected VAP (pulmonary culture on or after ventilator day 3 and a new antibiotic start within 2 days). Ventilator settings were minimal and stable for at least 3 days starting from the first day of antibiotics in 1290 of the 2549 patients with possible VAP (50.6%). Of these, 259 were prescribed 1-3 days of antibiotics and 1031 were prescribed >3 days of antibiotics. The clinical characteristics of these patients and their possible pneumonias are presented in Tables  1 and 2 .
Patients treated with short vs long courses were generally similar in sex, race, unit type, comorbidities, and initial clinical characteristics (Tables 1 and 2 ). Patients prescribed 1-3 days of antibiotics were older (63.4 vs 60.6 years; P = .02), more likely to be located in the medical ICU (27.0% vs 20.7%; P = .03), to have a history of renal failure (18.5% vs 9.9%; P < .001), and to have a higher predicted risk of hospital death on the first day of mechanical ventilation (mean, 30.2% vs 25.5%; P = .002). Conversely, more patients prescribed >3 days of antibiotics had positive cultures for S. aureus (25.6% vs 15.1%; P = .0003) and/or Klebsiella species (7.6% vs 3.1%; P = .01). Patients in the short-course group were prescribed a median of 2 days of antibiotics (interquartile range [IQR], 1-3 days), compared with 9 days (IQR, 6-12 days) for those in the long-course group.
Unadjusted outcomes for the 2 groups are shown in Table 2 . There were no significant differences in mean duration of mechanical ventilation, hospital length of stay, or hospital mortality rates. The median number of days from antibiotic start to extubation and hospital discharge was longer for patients prescribed >3 days of antibiotics. Outcomes adjusted for possible confounders are shown in Table 3 . There were no statistically significant differences between the 2 groups in hazard ratios (HRs) for time to extubation alive (HR, In all cases, the point estimates for these outcomes favored patients treated with the shorter course of antibiotics (HRs were >1 for time to extubation alive and time to hospital discharge alive and <1 for ventilator death and hospital death).
The results of all 3 sensitivity analyses using propensity scores mirrored the primary analysis (Table 3) . For the primary propensity analysis using all patients, we were able to identify matched controls for 257 of the 259 patients treated with 1-3 days of antibiotics. Propensity matching successfully eliminated all measured differences between short-course and long-course patients (Tables 1 and 2 ). There were no significant differences in unadjusted or adjusted outcomes for duration of mechanical ventilation, ventilator death, time to hospital discharge alive, or hospital death between short-vs long-course patients (Table 3) . These findings further persisted when restricting the analysis to patients with a new diagnosis code for pneumonia concurrent with their respiratory specimen and antibiotic start dates, and when restricting the analysis to patients with ≥25 neutrophils per low-power field and positive cultures for potentially pathogenic organisms.
DISCUSSION
Among patients treated for possible VAP with minimal ventilator settings sustained for at least 3 days, we were unable to identify any differences in outcomes between patients treated with 1-3 days of antibiotics vs those treated with >3 days of antibiotics. The lack of differences between these 2 groups persisted when restricting the study population to propensity-matched pairs, to patients with diagnosis codes for VAP, and to patients with ≥25 neutrophils per low-power field and positive cultures for potentially pathogenic organisms. These observations suggest the possibility that patients with suspected VAP but minimal and stable ventilator settings can be adequately managed with very short courses of antibiotics. If these findings are confirmed, assessing ventilator settings may prove to be a simple and objective strategy to identify potential candidates for early antibiotic discontinuation. Clinicians will simply need to track patients' ventilator settings: Those with daily minimum PEEP of ≤5 cm H 2 O and daily minimum FiO 2 <40% for at least 3 days from the first day of antibiotics may be suitable candidates for early antibiotic discontinuation.
Screening daily ventilator settings is attractive insofar as it is simple, inexpensive, and does not require specialized laboratory tests. This approach has the potential to become a valuable supplement or complement to existing strategies to identify candidates for early antibiotic discontinuation. Existing strategies include clinical judgment, Clinical Pulmonary Infection Score (CPIS) measurement, and serial procalcitonin assays. Clinical judgment requires clinicians to weigh patients' clinical signs and clinical trajectories to identify those in whom pneumonia is either unlikely or in whom pneumonia has been adequately treated. This strategy has been shown to decrease antibiotic utilization, is theoretically robust, and is closest to the ideal of the physician as a rational decision maker [26] . In practice, however, clinicians are often uncertain about the diagnosis of VAP and many defer to guidelines' headline recommendations to treat VAP for 7-8 days regardless of their particular patient's trajectory [17, 27] . At Johns Hopkins Hospital, for example, a multidisciplinary adjudication committee reviewed the evolution of clinical signs, chest radiographs, and microbiological specimens of all patients diagnosed with VAP in 6 ICUs over a 1-year period [5] . The adjudication panel determined that by treatment day 3 it was apparent that 158 of 231 (74%) patients diagnosed with VAP most likely did not have VAP. Frontline clinicians nonetheless continued antibiotics in 120 of 158 (76%) of these patients, on average for a total of 9.9 days per patient. Providing clinicians with simple, objective, quantitative clinical signs (ie, daily minimum PEEP and FiO 2 ) that they can use to identify appropriate candidates for antibiotic discontinuation may enhance their comfort and willingness to stop antibiotics.
The CPIS has been proposed as a tool to help clinicians systematize their assessment of VAP and its clinical trajectory. The CPIS assigns patients 0-2 points for each of 6 clinical signs: temperature, white blood cell count, radiographic findings, pulmonary secretions, arterial partial pressure of oxygen (PaO 2 ):FiO 2 ratio, and Gram stain or culture results. Patients with a score of >5 or >6 (depending on the study) are deemed to have VAP [28, 29] . The score was originally designed as a diagnostic aid, but at least 1 randomized controlled trial has demonstrated that it may help with antibiotic de-escalation. Singh and colleagues randomized 81 patients with suspected VAP but low CPIS to 3 days of ciprofloxacin monotherapy vs routine care. Patients randomized to short-course ciprofloxacin were prescribed significantly fewer days of antibiotics but had similar outcomes to patients in the usual-care arm [30] . The CPIS score is not ideal for informing antibiotic de-escalation, however, insofar as it correlates poorly with histologically proven pneumonia, it is complicated and subjective to calculate, and it is not in widespread use in routine critical care practice. Daily ventilator setting surveillance by contrast only requires 2 data points (PEEP and FiO 2 ) and measurement is objective.
Procalcitonin surveillance is a third strategy to inform antibiotic discontinuation. Clinical trials have evaluated daily procalcitonin monitoring paired with advice to clinicians to stop antibiotics if the relative level of procalcitonin drops by >80% from baseline and /or if the absolute level of procalcitonin falls below a specified threshold. Bouadma and colleagues, for example, randomized 630 critically ill patients with suspected bacterial infections to daily procalcitonin monitoring vs usual care [31] . Patients assigned to daily procalcitonin monitoring were prescribed significantly fewer days of antibiotics compared to usual care (absolute difference, 2.7 days [95% CI, 1.4-4.1]) without any apparent evidence of harm. These findings held true in the subset of patients with suspected VAP, were mirrored by a second trial of procalcitonin monitoring restricted solely to patients with VAP, and were further affirmed in a patient-level meta-analysis that pooled these 2 trials together [31] [32] [33] . Procalcitonin monitoring is attractive insofar as it provides clinicians with a tangible measure they can use to justify stopping antibiotics. This strategy is not ideal, however, because procalcitonin assays are not available in all hospitals, they can sometimes take hours to days to return, they incur costs, and they can be difficult to interpret as there are different versions of the assay and different cutoffs for stopping antibiotics [31] [32] [33] [34] . Daily ventilator setting surveillance, by contrast, is universally available, is equally quantitative and concrete, does not incur delay, and does not incur costs. Hazard ratios >1 indicate a greater probability of extubation per day and hence less time to extubation alive and hospital discharge. Hazard ratios <1 indicate a lower probability of death per day and hence greater overall probability of survival.
Abbreviations: CI, confidence interval; HR, hazard ratio; VAP, ventilator-associated pneumonia.
Our findings must be interpreted within the context of the limitations of the study. This was a retrospective observational study; hence, our findings may be confounded by unmeasured differences between the short-course and long-course populations. In particular, clinicians may have selected patients for shorter courses because they were less ill, because their pneumonias were less severe, or because they were less confident about the diagnosis. We tried to adjust for these factors by incorporating variables for patient comorbidities, severity of illness, temperature, white blood cell count, vasopressor requirement, pulmonary specimen characteristics, and culture results. In addition, we performed multiple sensitivity analyses using propensity scores to improve matching between cohorts, to restrict the population to patients with unambiguous diagnoses of VAP, and to restrict the population to patients with purulent pulmonary secretions growing potentially pathogenic organisms. The propensity-matched analyses eliminated observable differences between short-course and long-course patients. Nonetheless, residual differences in unmeasured patient traits may have persisted. Additional limitations of our study include the single-center setting, our imputation that antibiotics were prescribed for pneumonia and not for another indication, and the difficulty calculating duration of antibiotics in patients prescribed overlapping courses of antibiotics for the same or different indications. Antibiotics started ≥3 days prior to VAP onset and continued for >3 days beyond VAP onset were not counted in our study as new antibiotics, but they may have mitigated potential differences between the short and long treatment groups.
In sum, patients treated for suspected VAP who have minimal and stable ventilator settings for at least 3 days appear to have similar outcomes when treated with antibiotics for ≤3 days or >3 days. These observations merit further evaluation in a randomized controlled trial. If these observations are confirmed, then serial ventilator settings surveillance could be a valuable tool to help clinicians identify suitable candidates for early antibiotic discontinuation.
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